Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 09, 2025, titled "Senores Pharmaceuticals acquires ANDA for Tramadol Tablets from APDMPharmaceuticals.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals, through its wholly-owned US subsidiary (Senores Pharmaceuticals, Inc.), has signed an agreement to acquire the USFDA-approved ANDA for Tramadol Tablets from APDM Pharmaceuticals. Tramadol is an opioid pain medication with a US market size of approximately USD 61.95 million (per IQVIA, MAT December 2024) or USD 119.09 million (per Symphony, MAT March 2025), depending on data source. The acquisition will be funded entirely from the company's IPO proceeds, which is consistent with the stated objectives in its Red Herring Prospectus. Senores' current US portfolio includes 61 ANDAs and 22 CMO/CDMO commercial products.
This acquisition is funded by IPO money (no new debt), aligns with the company's stated IPO objectives, and adds a meaningful US-market product to its portfolio. Positive for growth prospects, though the actual financial impact will depend on commercial launch and market share capture.